Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

Upadacitinib Achieved Rapid Response in Biologic-Refractory Immune Checkpoint Inhibitor-Related Enterocolitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions.

The journal of allergy and clinical immunology. In practice·2026
Same author

YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Future oncology (London, England)·2026
Same author

YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Dec 5, 2025

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.6K

Immune-Directed Molecular Imaging Biomarkers.

Neeta Pandit-Taskar1, Michael A Postow2

  • 1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.

Seminars in Nuclear Medicine
|October 16, 2020
PubMed
Summary
This summary is machine-generated.

New imaging biomarkers are needed for cancer therapies. Radiolabeled antibodies and small molecules show promise for assessing treatment effectiveness and patient outcomes in oncology.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

Related Experiment Videos

Last Updated: Dec 5, 2025

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.6K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

Area of Science:

  • Oncology
  • Medical Imaging
  • Biomarker Discovery

Background:

  • Conventional imaging methods have limitations with novel cancer therapies like targeted therapeutics and immunotherapy.
  • Fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is not optimal for assessing immune therapies.
  • There is a significant need for imaging biomarkers that can predict treatment response and patient prognosis.

Purpose of the Study:

  • To review the development and potential of novel imaging agents for cancer management.
  • To highlight the unmet need for pharmacodynamic and prognostic imaging biomarkers.
  • To discuss the promise of radiolabeled antibodies and small molecules in precision oncology.

Main Methods:

  • Review of preclinical and early human studies on novel imaging agents.
  • Focus on radiolabeled antibodies and small molecules targeting specific cancer pathways (e.g., epidermal growth factor receptor).
  • Exploration of immune-directed imaging agents and their potential as biomarkers.

Main Results:

  • Radiolabeled antibodies and small molecules offer specific assessment of target expression and concentration.
  • Early studies targeting the epidermal growth factor receptor pathway show potential.
  • Immune-directed imaging agents show promise as biomarkers, with preliminary studies being encouraging.

Conclusions:

  • Novel imaging agents, including radiolabeled antibodies and small molecules, are under development for cancer management.
  • Targeted imaging of biomarkers like CA19.9 and CA-IX is being explored.
  • Larger, well-designed studies are required to validate these novel agents as clinical biomarkers for patient management.